A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Summary

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Schizophrenia
• Schizoaffective Disorder
• Bipolar Disorder
• Major Depressive Disorder
• Tardive Dyskinesia

Eligibility basics and study details

Study type

Interventional

Phase

Phase 4

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Neurocrine Biosciences

Last updated on ClinicalTrials.gov

September 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites